Trial · NCT06317051
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 25
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To assess the impact of dapagliflozin vs. placebo on weight reduction | 24 weeks | Mean reduction change in body weight across treatment arms at 24 weeks, defined as absolute body weight change. |
| Primary | To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe on low-density lipoproteins (LDL) concentration | 24 weeks | Mean change in LDL as absolute change from baseline to 24 weeks across treatment arms |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on body mass index (BMI )- weight and height will be combined to report BMI in kg/m^2 | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on waist (cm) to hip (cm) ratio | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on waist (cm) to height (cm) ratio | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on systolic and diastolic blood pressure (mm Hg) | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on Atherosclerotic cardiovascular disease risk score (ASCVD) - calculation of a person's10-year risk (%) of having a cardiovascular problem. | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on fasting lipids including: Total Cholesterol (mmol/L), LDL (mmol/L), High-Density Lipoproteins (HDL) (mmol/L), Triglycerides (mmol/L) | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on fasting glucose (mmol/L) | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on haemoglobin A1C (%) | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on measures of fatty liver disease: Liver Function Tests - Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) (U/L), FibroScan (kPa) | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on inflammatory biomarkers (tested centrally on stored research samples) | 48 weeks | |
| Secondary | To assess the impact of dapagliflozin vs. placebo from baseline to 48 weeks on Serious adverse events. | 48 weeks | |
| Secondary | To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe from baseline to 48 weeks on fasting lipids including: Total Cholesterol (mmol/L), LDL (mmol/L), High-Density Lipoproteins (HDL) (mmol/L), Triglycerides (mmol/L) | 48 weeks | |
| Secondary | To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe from baseline to 48 weeks on Atherosclerotic cardiovascular disease risk score (ASCVD) - calculation of a person's10-year risk (%) of having a cardiovascular problem. | 48 weeks | |
| Secondary | To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe from baseline to 48 weeks on inflammatory biomarkers (tested centrally on stored research samples) | 48 weeks | |
| Secondary | To assess the impact of pitavastatin vs. rosuvastatin/ezetimibe from baseline to 48 weeks on serious adverse events | 48 weeks | |
| Other | Change in body weight from baseline to Week 96 | Baseline to Week 96 | Absolute change in body weight, measured in kilograms, from baseline to Week 96. |
| Other | Change in waist-to-hip and waist-to-height ratios from baseline to Week 96 | Baseline to Week 96 | Change in waist-to-hip ratio and waist-to-height ratio from baseline to Week 96. |
| Other | Change in systolic and diastolic blood pressure from baseline to Week 96 | Baseline to Week 96 | Change in resting systolic and diastolic blood pressure, measured in mmHg, from baseline to Week 96. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06317051/registered